IDH1 and acute myeloid leukemia: Mutations in IDH1 or IDH2 are detected in approximately 20% of AML patients inducing amino acid changes in conserved residues resulting in neomorphic enzymatic function and production of an oncometabolite, 2-hydroxyglutarate, leading to DNA hypermethylation, aberrant gene expression, cell proliferation and abnormal differentiation (Dang et al., 2016; Montalban-Bravo and DiNardo 2018) .